China challenges US in new drugs after industry transformation



China challenges US in new drugs after industry transformation
In barely a decade, China has transformed from a maker of cheap generic copies of Western medicines into a global powerhouse of pharmaceutical innovation.
The country now only trails the United States in novel drugs under development, with a 29 per cent share, according to McKinsey. International pharmaceutical companies are beating a path to China’s shores to license next-generation treatments for cancer, autoimmune diseases and other disorders.
Government support, including regulatory and…

  • Related Posts

    DBS bets on Hong Kong as wealth fortress

    [The content of this article has been produced by our advertising partner.] DBS Bank (Hong Kong) Limited (“DBS Hong Kong”) is pressing ahead with a three-year plan to recruit 100…

    Continue reading
    Hong Kong executives trail employees in AI adoption: McKinsey

    The majority of Hong Kong’s white-collar workers are embracing artificial intelligence in their daily work, but executives’ reluctance to use the technology risks slowing enterprise-wide adoption, according to a survey…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *